期刊
JCI INSIGHT
卷 5, 期 18, 页码 -出版社
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/jci.insight.139983
关键词
-
资金
- Canadian Institutes of Health Research [MOP-142221, PJT-153095]
- National Institute of Diabetes & Digestive & Kidney Diseases [5R01DK075302]
- Cystic Fibrosis Foundation Therapeutics
- Cystic Fibrosis Canada
- Canada Foundation for Innovation (CFI) [32616, 228340]
Based on its clinical benefits, Trikafta - the combination of folding correctors VX-661 (tezacaftor VX-445 (elexacaftor), and the gating potentiator VX-770 (ivacaftor) - was FDA approved for treatment of patients with cystic fibrosis (CF) carrying deletion of phenylalanine at position 508 (F508del) of the CF transmembrane conductance regulator (CFTR) on at least 1 allele. Neither the mechanism of action of VX-445 nor the susceptibility of rare CF folding mutants to Trikafta are known. Here, we show that, in human bronchial epithelial cells, VX-445 synergistically restores F508del-CFTR processing in combination with type I or II correctors that target the nucleotide binding domain 1(NBD1) membrane spanning domains (MSDs) interface and NBD2, respectively, consistent with a type Ill corrector mechanism. This inference was supported by the VX-445 binding to and unfolding suppression of the isolated F508del-NBD1 of CFTR. The VX-661 plus VX-445 treatment restored F508del-CFTR chloride channel function in the presence of VX-770 to approximately 62% of WT CFTR in homozygous nasal epithelia. Substantial rescue of rare misprocessing mutations (513F, R31C, G8SE, E92K, V520F, M1101K, and N1303k), confined to MSD1, MSD2, NBD1, and NBD2 of CFTR, was also observed in airway epithelia, suggesting an allosteric correction mechanism and the possible application of Trikafta for patients with rare misfolding mutants of CFTR.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据